Back to Search
LAWRENCE BLASZKOWSKY, MD
MD
Medical Oncology Physician
NPI: 1225028137IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
80772(MA)
Hematology (Internal Medicine) Physician
Internal Medicine — Hematology
Code: 207RH0000X
80772(MA)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
OTHER
Class of 1990
Research & Publications (18)
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
PMID 19565187·Invest New Drugs·2010
3-trial
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.
PMID 19139178·Ann Oncol·2009
3-trial
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.
PMID 19047305·J Clin Oncol·2009
3-trial
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
PMID 19470923·J Clin Oncol·2009
8-other
MDM2 promoter polymorphism and pancreatic cancer risk and prognosis.
PMID 18559624·Clin Cancer Res·2008
8-other
Case report: an unusual case of adrenal neuroblastoma in pregnancy.
PMID 18305060·Oncologist·2008
5-case
Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.
PMID 17597402·Dig Dis Sci·2008
3-trial
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer.
PMID 17483115·Ann Oncol·2007
3-trial
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
PMID 17947726·J Clin Oncol·2007
8-other
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.
PMID 17583545·Cancer·2007
3-trial
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.
PMID 17026790·Clin Colorectal Cancer·2006
3-trial
Laparoscopic scar: a mimicker of Sister Mary Joseph's nodule on positron emission tomography/CT.
PMID 16981954·Australas Radiol·2006
5-case
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.
PMID 16622265·J Clin Oncol·2006
3-trial
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
PMID 16258121·J Clin Oncol·2005
3-trial
Case records of the Massachusetts General Hospital. Case 23-2005. A 57-year-old man with a mass in the liver.
PMID 16049213·N Engl J Med·2005
5-case
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
PMID 14745444·Nat Med·2004
3-trial
High dose radiation therapy and chemotherapy as induction treatment for stage III nonsmall cell lung carcinoma.
PMID 11064351·Cancer·2000
8-other
A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296).
PMID 10765123·Oncology·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 55 FRUIT ST, HEMATOLOGY/ONCOLOGY
BOSTON, MA 02114 - Phone
- (617) 724-1700
Quick Facts
- NPI
- 1225028137
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 2
- Years in Practice
- 36
- Publications
- 18
Are you this provider?
Claim Your Profile